Infinitas Capital

Einwert is the first European hybrid appraiser that reimagines real estate valuation through an ESG-compliant value experience. The company has developed a real estate value management platform designed to empower appraisers with digital technology, enhancing market transparency and providing sustainability insights. By replacing manual processes with intelligent parameter determination, Einwert offers accurate, sustainability-driven formal valuations. This innovative approach enables clients, particularly real estate investors, to make smarter and more future-oriented decisions that are essential for their business growth.

Wonder Brands is a Latin American startup focused on partnering with successful digital brands to enhance their growth potential. The company achieves this by injecting substantial investments into its partner brands, thereby increasing their working capital, marketing capabilities, and operational resources. In addition to financial support, Wonder Brands provides expertise in areas such as technology, digital marketing, supply chain management, and administration. This comprehensive approach allows clients to better respond to consumer needs while diversifying their product offerings and expanding their target audiences. Through these strategic partnerships, Wonder Brands aims to foster significant growth for the brands it collaborates with.

Operator of a clinical-stage biopharmaceutical company intended to develop therapies for Alzheimer's disease. The company developed a drug that is an orally administrated small molecule treatment, that enhances the neurotransmission in the brain and improves both cognition and independent global function, it is phase three trial-ready, enabling medical practitioners to use neurotransmission and improve both cognition and independent global function.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

Opeartor of a digital platform intended to convert real estate assets into cash assets. The company provides partial real estate sales of the property places customers at the center of all our considerations and efforts and relies on tailor-made, individual solutions, enabling customers to keep all decision-making options and buy back the part sold at any time or sell the entire property.

Exporo AG is a Hamburg-based company that operates an online real estate crowdfunding platform in Germany. Founded in 2014 by Simon Brunke, Björn Maronde, Tim Bütecke, and Julian Oertzen, Exporo connects private investors with real estate developers seeking capital. The platform offers an accessible and transparent way for individuals to invest in real estate projects that were traditionally available only to institutional investors. By allowing low minimum investments, Exporo enables retail investors to diversify their portfolios while benefiting from attractive interest rates. The company has grown significantly and now employs over 120 people, continuously evolving to meet the needs of both investors and developers in the changing financial landscape.

Einwert is the first European hybrid appraiser that reimagines real estate valuation through an ESG-compliant value experience. The company has developed a real estate value management platform designed to empower appraisers with digital technology, enhancing market transparency and providing sustainability insights. By replacing manual processes with intelligent parameter determination, Einwert offers accurate, sustainability-driven formal valuations. This innovative approach enables clients, particularly real estate investors, to make smarter and more future-oriented decisions that are essential for their business growth.

AMZSCALE is an agency specializing in Amazon fulfillment services designed to assist third-party eCommerce businesses. Comprising a team of experienced eCommerce professionals who have successfully built and sold their own Amazon brands, the agency provides a range of services aimed at facilitating business growth. These services include detailed research and sourcing, operational excellence, sales infrastructure development, and brand optimization. By leveraging their practical knowledge, AMZSCALE enables clients to enhance their operational capabilities and scale their businesses effectively in the competitive Amazon marketplace.

FORME Life is a modular smart home gym and home fitness system for fitness and strength workouts. The company combines advanced linked fitness devices with coaching and personal training provided by real people to provide an immersive experience and improve results for both clients and trainers.

Storypod is a company focused on fostering children's love of learning through a screen-free, interactive audio platform designed for young users. The platform utilizes a smart audio system powered by RFID-enabled yarn figurines, read-along audiobooks, and trivia cards, allowing children to engage with classic stories, music, and educational games. By providing stage-based content, Storypod aims to support parents, grandparents, and educators in nurturing smart, healthy, and resilient kids while promoting independent learning in a fun and engaging manner.

Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

Customuse is a developer of virtual apparel design software that allows users to create and sell wearable augmented reality outfits for virtual avatars. The platform features an intuitive interface and unique templates, making it easy for users to bring their product ideas to life. By enabling the design of virtual clothing, Customuse facilitates the promotion of brands and enhances audience interaction within popular games and on social media. The software empowers users to quickly market their designs in augmented and virtual reality environments, thereby expanding their reach and engagement.

Olsam Group is a technology-driven commerce company that specializes in acquiring and operating leading Amazon third-party and direct-to-consumer eCommerce brands on a global scale. The company conducts thorough due diligence on potential acquisitions, structures equitable cash deals, and transfers assets such as website domains and software tools to its ownership. Once acquired, Olsam focuses on scaling these brands through strategic capital investment and supply chain expertise. This approach allows business owners the flexibility to fully exit their operations or remain involved as desired.

Bullish Global is a new blockchain-based cryptocurrency exchange designed to combine the performance, user privacy, and compliance offered by central order book technology with the vertically integrated user benefits of decentralized finance (DeFi) market architecture.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

nextmarkets GmbH, founded in 2014 and headquartered in Cologne, Germany, specializes in developing a user-friendly web and mobile trading platform aimed at private investors. The platform allows users to intuitively trade a wide range of financial instruments, including equities, foreign exchange, bonds, and commodities. Recognizing the challenges faced by private investors—many of whom struggle in the stock market due to behavioral economic factors—nextmarkets provides educational resources and trading strategies to enhance users' understanding of market dynamics. By equipping investors with the necessary tools and knowledge, nextmarkets aims to promote sustainable and informed trading practices.

Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. Founded in 1999, the company specializes in developing precision cancer therapeutics, particularly next-generation immunotherapies. Sensei's proprietary drug discovery platform, ImmunoPhage, focuses on understanding the tumor microenvironment to create novel biologics that target tumor-specific antigens and activate both the innate and adaptive immune systems. The company is working on a range of investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which aim to address unmet needs in cancer treatment by selectively disabling immunosuppressive signals or activating immunostimulatory signals within the tumor microenvironment. Through its innovative approach and collaboration with experts in biology, immunology, and oncology, Sensei Biotherapeutics seeks to transform cancer treatment and improve outcomes for patients.

Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

Booster Therapeutics is a biotechnology company focused on developing innovative medicines aimed at addressing diseases associated with aging. The company specializes in regulating cellular homeostasis, a process essential for maintaining balance within cells. By targeting the cellular systems responsible for this regulation, Booster Therapeutics aims to eliminate toxic accumulations that can lead to various aging-related conditions. Through its research and development efforts, the company seeks to provide effective treatments that can prevent and manage these diseases, enhancing overall health and longevity.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.